Literature DB >> 1153692

Halothane-related hepatitis. A clinical study of twenty-six cases.

P J Moult, S Sherlock.   

Abstract

Twenty-six patients are described who had otherwise unexplained hepatitis after halothane anaesthesia. Twenty-four (92 per cent) had multiple exposures, and 11 (42 per cent) died. In eight patients a characteristic pattern of delayed postoperative pyrexia has been found. Obesity was common, but the clinical features and complications were those of any severe hepatitis. Obesity, early onset of jaundice after anaesthesia, and low thrombotest, were associated with a fatal outcome. None of those who were followed up after recovery developed clinical or biochemical evidence of chronic liver disease. The differential diagnosis of postoperative jaundice is discussed, and it is shown that halothane patients with hepatic encephalopathy are significantly older (25.4 plus or minus 11.6 years) than those referred to this unit with viral hepatitis of equal severity (34.1 plus or minus 16.4 years). Unexplained jaundice or delayed pyrexia after a previous administration of halothane should be a contraindication to its further use.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1153692

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  16 in total

Review 1.  Halothane and liver damage.

Authors:  D Rosenak; A Halevy; R Orda
Journal:  Postgrad Med J       Date:  1989-03       Impact factor: 2.401

2.  Diagnosis of halothane-related hepatitis.

Authors:  P J Moult; S Sherlock
Journal:  Proc R Soc Med       Date:  1975-12

Review 3.  Drug hepatotoxicity.

Authors:  J A Timbrell
Journal:  Br J Clin Pharmacol       Date:  1983-01       Impact factor: 4.335

Review 4.  Halothane anaesthesia and liver damage.

Authors:  J Neuberger; R Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1984-10-27

5.  Hepatic reactions to drugs.

Authors:  S Sherlock
Journal:  Gut       Date:  1979-07       Impact factor: 23.059

6.  Effects of saikosaponins on hepatic damage induced by halothane and hypoxia in phenobarbital-pretreated rats.

Authors:  Teruhiro Nishiura; Seishiro Marukawa; Hiroatsu Ishida; Machiko Orita; Hiroko Abe
Journal:  J Anesth       Date:  1994-03       Impact factor: 2.078

Review 7.  Halothane and hepatitis. Incidence, predisposing factors and exposure guidelines.

Authors:  J M Neuberger
Journal:  Drug Saf       Date:  1990 Jan-Feb       Impact factor: 5.606

8.  Effect of surgery under general anaesthesia on antipyrine clearance.

Authors:  D Pessayre; H Allemand; C Benoist; F Afifi; M François; J P Benhamou
Journal:  Br J Clin Pharmacol       Date:  1978-12       Impact factor: 4.335

9.  Impact of obesity on the toxicity of a multi-ingredient dietary supplement, OxyELITE Pro™ (New Formula), using the novel NZO/HILtJ obese mouse model: Physiological and mechanistic assessments.

Authors:  Charles M Skinner; Isabelle R Miousse; Laura E Ewing; Vijayalakshmi Sridharan; Maohua Cao; Haixia Lin; D Keith Williams; Bharathi Avula; Saqlain Haider; Amar G Chittiboyina; Ikhlas A Khan; Mahmoud A ElSohly; Marjan Boerma; Bill J Gurley; Igor Koturbash
Journal:  Food Chem Toxicol       Date:  2018-09-30       Impact factor: 6.023

10.  Halothane hepatitis in Iran: a review of 59 cases.

Authors:  Payam Eghtesadi-Araghi; Amirali Sohrabpour; Homayoon Vahedi; Mehdi Saberi-Firoozi
Journal:  World J Gastroenterol       Date:  2008-09-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.